This transcript has been edited for clarity. Oliver Freudenreich, MD: Hello. I am Dr Oliver Freudenreich. For this Care Cues conversation today, I'm joined by my colleague, Dr Corinne Cather. We're ...
A 2015 study comparing schizophrenia patients who received oral or injectable antipsychotic medications found no difference in relapse rates between the groups. Now, a follow-up study published August ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA ® is FDA approved to treat schizophrenia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results